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liofemoral deep vein thrombosis (DVT), defined as DVT that involves the iliac or common femoral vein (with or without involvement of additional veins), often causes functional obstruction of venous outflow of the involved leg. 1, 2 These patients are phenotypically distinct from patients with calf or femoral-popliteal DVT, based on more frequent recurrent venous thromboembolic events, more frequent postthrombotic syndrome (PTS), and more severe PTS. 1, [3] [4] [5] [6] [7] Preliminary studies of catheter-directed thrombolysis and related methods have suggested that these strategies may be most useful in patients with iliofemoral DVT compared with those with less extensive proximal DVT, and that the occurrence and degree of thrombus clearance may correlate with clinical outcome. [8] [9] [10] [11] [12] [13] The biological plausibility that iliofemoral DVT should be recognized as a distinct entity in the anatomic spectrum of acute DVT is rooted in the anatomy and physiology of lower extremity venous return and the observation that venous recanalization occurs less often in patients with iliofemoral versus more distal DVT who were treated with anticoagulation alone or systemic thrombolysis. 14, 15 As the entire volume of venous blood return is directed through the common femoral and iliac veins, obstruction of this channel results in marked postthrombotic venous hypertension 16 and severe postthrombotic morbidity. [3] [4] [5] [6] [7] The main results of the ATTRACT trial (Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis), the largest randomized trial evaluating catheter-based intervention for acute proximal DVT, were recently reported. 17, 18 This study found no reduction of 2-year PTS frequency (the study's primary outcome) or improvement in health-related quality of life (QOL) in patients treated with pharmacomechanical catheter-directed thrombolysis (PCDT) compared with those treated with anticoagulation alone, although there was a reduction in the severity of PTS in the PCDT-treated group. Importantly, patients in this study were stratified by the most proximal extent of their DVT (iliofemoral versus femoral-popliteal) before randomization, permitting a valid analysis of the outcomes of these 2 distinct anatomic-clinical presentations. The purpose of the present analysis is to report the benefits and risks of PCDT in the patients in the AT-TRACT Trial who presented with acute iliofemoral DVT.
METHODS

Study Organization
The study design and the main study results for the overall ATTRACT cohort have been previously described. 17, 18 In brief, this was a National Institutes of Health (NIH)-sponsored, Phase III, multicenter, randomized, open-label, assessor-blinded, parallel 2-arm, controlled clinical trial (URL: https://bloodclotstudy. wustl.edu/attract/. Unique identifier: NCT00790335). All patients provided written informed consent. The study was approved by the Institutional Review Boards at all participating centers. The authors and Steering Committee are solely responsible for the design and conduct of the study, all analyses, and the writing of this article. The data and study materials will be made available to other researchers in accordance with the NIH Public Access Policy, at www.clinicaltrials.gov or by contacting the Corresponding Author.
Patient Population, Stratification, and Randomization
Patients presenting with DVT in the femoral or a more proximal vein with symptoms of 14 days or less were enrolled from 56 centers in the United States (US). Patients were stratified by clinical center and by the most proximal extent of their DVT, that is, whether the DVT involved the iliac or common femoral vein (iliofemoral DVT; this term applied whether or not more caudal veins were also involved) or not (femoralpopliteal DVT).
1,2 After stratification, patients were randomized in a 1:1 ratio to receive either PCDT with anticoagulation (PCDT Arm), or anticoagulation alone (No-PCDT Arm), and followed for 2 years. In this analysis, we report exclusively on the 391 patients with iliofemoral DVT; the patients with femoral-popliteal DVT are reported elsewhere.
Treatments
All patients were treated with initial and long-term anticoagulation consistent with published guidelines, 19, 20 and were
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What Is New?
• Outcomes are reported on a subgroup of 391 patients with acute iliofemoral deep-vein thrombosis (DVT) in whom pharmacomechanical catheter-directed thrombolysis (PCDT) was evaluated within a large multicenter, randomized, controlled trial (ATTRACT).
• In patients with acute iliofemoral DVT, PCDT does not influence the occurrence of the postthrombotic syndrome (PTS) or recurrent venous thromboembolism through 24 months.
• In patients with acute iliofemoral DVT, PCDT does appear to provide greater reduction in acute leg pain and swelling through 30 days follow-up, as well as reduced PTS severity, reduced moderateor-severe PTS, and greater improvement in venous disease-specific quality of life through 24 months.
What Are the Clinical Implications?
• The findings support early use of PCDT in patients with acute iliofemoral DVT who have severe symptoms, low bleeding risk, and who attach greater importance to a reduction in early and late symptoms than to the risks, costs, and inconvenience of PCDT. 
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provided knee-high 30-to 40-mm Hg ankle gradient elastic compression stockings (BSN Medical, Charlotte, NC) at their 10-day follow-up visit and every 6 months. PCDT was performed as described elsewhere by board-certified physicians whose credentials were approved by the trial leadership, using methods consistent with published guidelines. 21, 22 Recombinant tissue plasminogen activator (rt-PA; alteplase, Activase ® , Genentech, South San Francisco, CA) was infused into the thrombus using 1 of 3 methods: a standard multi-sidehole catheter (infusion-first), the AngioJet Rheolytic Thrombectomy System (Boston Scientific, Malborough, MA; power pulse-spray or rapid lysis method), or the Trellis Peripheral Infusion System (Covidien Inc, Mansfield, MA [now Medtronic]; isolated thrombolysis). rt-PA dosing limits were: (1) 0.01 mg/ kg/hr, not to exceed 1.0 mg/hr; (2) no more than 30 hours infusion; (3) no more than 25 mg in any 1 procedure session; and (4) no more than 35 mg total. After initial rt-PA delivery, physicians could use balloon maceration, catheter aspiration, thrombectomy devices, or balloon angioplasty to clear residual thrombus. Stent placement was encouraged for obstructive lesions in the iliac vein or common femoral vein causing ≥50% diameter narrowing, >2 mm Hg mean pressure gradient, or robust collateral filling on venography. Patients received heparinbased anticoagulation during PCDT, as previously described.
17,18
Outcome Assessments
Patient outcomes were assessed at 10 and 30 days, and at 6, 12, 18, and 24 months after randomization, by clinicians who were blinded to treatment allocation. The adjudicators of safety and efficacy outcomes were also unaware of the treatment assignments.
PTS, defined as a Villalta score of ≥5 or a venous ulcer in the leg with the index DVT that occurred at any 1 or more assessments between the 6-month and 24-month follow-up visits (inclusive), was the study's primary efficacy outcome. 23, 24 The Villalta scale rates the severity of 5 patient-reported symptoms (pain, cramps, heaviness, pruritus, paresthesia) and 6 clinician-observed signs (edema, skin induration, hyperpigmentation, venous ectasia, redness, pain during calf compression), with each item scored from 0 to 3. Points for symptoms and signs are summed into a total score (range 0-33), and patients can be categorized as having no PTS (score 0-4), mild PTS (score 5-9), moderate PTS (score [10] [11] [12] [13] [14] , or severe PTS (score ≥15, or presence of ulcer). Development of PTS was also attributed to patients if they underwent an unplanned endovascular procedure to treat severe venous symptoms beyond 6 months after randomization, unless there was a Villalta score <5 in the previous 4 weeks.
The severity of PTS was evaluated at 6, 12, 18, and 24 months using the Villalta score and the Venous Clinical Severity Score (VCSS) 25 as continuous measurements. In addition, using the Villalta score, the presence of moderate or severe PTS (Villalta score ≥10, or an ulcer) or severe PTS (Villalta score ≥15, or an ulcer) were assessed as secondary outcomes. Using the VCSS (ranges from 0-27, with higher scores indicating more severe PTS), the presence of PTS (VCSS score ≥4) and severe PTS (VCSS score ≥8) were also assessed using previously published criteria. 26 Generic health-related QOL was assessed with the SF-36 Health Status Survey, 27 and venous disease-specific QOL was assessed with the Venous Insufficiency Epidemiological and Economic Study Quality of Life measure (VEINES-QOL). 28 Leg pain and leg swelling were assessed at baseline, 10 days, and 30 days using a 7-point Likert pain scale and by measuring calf circumference. 29 Patients receiving PCDT had the amount of thrombus removal quantified by independent central readers using the proximal-vein components of the Marder score. 30 Safety outcomes included bleeding, recurrent venous thromboembolism, and death, which were recorded throughout follow-up and summarized through 10 days and 24 months. Clinically overt bleeding was classified as major if it was associated with a fall in the hemoglobin level of at least 2.0 g/dL, transfusion of ≥2 U of red blood cells, or involvement of a critical site (eg, intracranial, intraspinal). 31 Less severe clinically overt bleeding was classified as minor.
Sample Size
Sample size for the entire ATTRACT study was 692 proximal DVT patients based on these assumptions: 30% of control patients would develop PTS between 6 and 24 months; PCDT would reduce PTS by ≥33%; 10% loss to follow-up; need to have 80% power to detect the hypothesized treatment effect; acceptance of a 2-sided α error of 0.05. We did not estimate the sample size for the iliofemoral DVT subgroup, prespecify the proportion of patients expected to have iliofemoral DVT, or require a minimum number of patients with iliofemoral DVT. A sample size of 391, corresponding to the number of patients in the current analysis, provides ≈80% power to detect (1) a 41% PTS reduction assuming a control proportion of 30%, and (2) an effect size (ie, mean difference divided by the SD) of at least 0.28, assuming a 2-sided α error of 0.05 with each type of analysis.
Statistical Analysis
Two types of analyses were performed: a modified intention-to-treat analysis (primary analysis) that included all randomized patients except those who did not have DVT at enrollment, and a per-protocol analysis (secondary analyses) that excluded patients who, within 7 days postrandomization, were randomized to PCDT but did not receive it, or who were randomized to control but had skin puncture for PCDT thrombolysis or any thrombolytic therapy.
Cumulative proportions were compared using the Cochran-Mantel-Haenszel test adjusted for clinical center. Treatment effects are summarized using stratum-adjusted risk ratios (RR) with their corresponding 95% confidence intervals (CI).
The mean Villalta, VCSS, and QOL assessments at each visit were estimated using piecewise linear regression growth curve models adjusting for clinical center and prespecified baseline covariates (age, sex, body mass index, race). Changes from baseline to 10 days and from baseline to 30 days for leg pain scores and calf circumferences in the index leg were compared using multiple linear regression, adjusted for clinical center. A supportive analysis modeled the values at 10 days and 30 days with the baseline value as a covariate. For the binary outcomes, interaction tests for subgroups were conducted using a logistic model with treatment, subgroup, and an interaction term as factors, with interaction P values calculated using Wald joint tests. The RRs and 99% CIs derived from the models were used to create the forest plots.
The analyses in this report are considered exploratory because, although they were prespecified, they are confined to a subgroup of the main trial.
RESULTS
Baseline Characteristics of Participants
Of the 692 patients in ATTRACT, 391 (57%) had iliofemoral DVT, of whom 196 were randomized to PCDT and 195 were randomized to No-PCDT ( Figure 1 ). Median age was 52 years, 53% were male, the index DVT was in the left leg in 64%, and symptoms were present for a median of 6 days ( Table 1) . Baseline characteristics were well balanced between the two treatment groups (Table 1 ).
Protocol and Treatment Adherence
Within 7 days after randomization, 4 patients assigned to No-PCDT had PCDT, and 6 patients assigned to PCDT did not have the procedure (Figure 1 ). These patients were excluded from the per-protocol analysis. PCDT was performed at a median 1 day postrandomization. Initial anticoagulant therapy, which was usually low molecular weight heparin or unfractionated heparin, was similar in the PCDT and No-PCDT patients ( Table 2 ). The initial rt-PA delivery method in PCDT Arm patients was the infusion-first method in 52% (median total rt-PA dose of 21 mg), the AngioJet method in 24% (median total rt-PA dose of 21 mg), and the Trellis method in 19% (median total rt-PA dose of 20 mg; PCDT not performed in 5%; Table 2 ). After initial rt-PA delivery, additional endovascular methods were used in 91% of patients, as summarized in Table 2 . Mean thrombus removal as assessed by pre-and post-PCDT venography was 86% (mean preprocedure and postprocedure Marder scores 12.0 and 3.0, respectively; change, −9.1; 95% CI, −8.2 to −10.0; P<0.001). The mean durations of anticoagulation before first permanent cessation during follow-up, use of antiplatelet therapy, and use of compression stockings were similar in the PCDT and No-PCDT patients ( Table 2 ).
Development of Postthrombotic Syndrome
In the intention-to-treat analysis using the study's primary outcome measure (Villalta scale), PTS developed in 96 of 196 (49%) PCDT Arm patients and in 100 of 195 (51%) No-PCDT Arm patients (RR, 0.95; 95% CI, 0.78-1.15; P=0.59) during 24 months follow-up (Table 3). In the per-protocol analysis and in all subgroups evaluated, the findings were similar ( Figure 2 , Table I in the online-only Data Supplement). Using the VCSS scale, PTS developed in 30% of PCDT Arm patients and in 40% of No-PCDT Arm patients (RR, 0.75; 95% CI, 0.57-0.98; P=0.034; Table 3 ). In the per-protocol analy- 
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Severity of Postthrombotic Syndrome
At 6, 12, 18, and 24 months, mean Villalta and VCSS scores were significantly lower in the PCDT Arm compared with the No-PCDT Arm (P<0.01 at all time-points, both analysis sets; Table 4 , Figure 3 ). 32 Moderate-or-severe PTS, as assessed by a Villalta scale score ≥10 or ulceration, developed in 36 (18%) patients assigned to PCDT and in 55 (28%) patients assigned to No-PCDT (RR, 0.65; 95% CI, 0.45-0.94; P=0.021; Table 3 ). The findings were similar in a per-protocol analysis (RR, 0.63; P=0.013; Table I in the online-only Data Supplement). For this outcome, patients' sex, race, symptom duration (0-1 versus 1-2 weeks), side of DVT, and baseline symptom severity did not influence the effect of PCDT. However, patients <65 versus ≥65 years old (P interaction=0.04) and those with versus without a major reversible DVT risk factor at diagnosis (P interaction=0.05) appeared less likely to develop moderate-orsevere PTS with use of PCDT (Figure 4 ).
Severe PTS, as assessed by a Villalta score ≥15 or ulceration, developed in 17 (8.7%) patients assigned to PCDT and in 30 (15%) patients assigned to No-PCDT (RR, 0.57; 95% CI, 0.32-1.01; P=0.048; Table 3 ). Severe PTS, as assessed by a VCSS score ≥8, developed in 13 (6.6%) patients assigned to PCDT and 28 (14%) patients assigned to No-PCDT (RR, 0.46; 95% CI, 0.24-0.87; P=0.013; Table 3 ). These findings were similar in per-protocol analyses (Table I in the online-only Data Supplement). Ulceration developed in 9 (4.6%) patients assigned to PCDT and in 12 (6.2%) patients assigned to No-PCDT (RR, 0.75; 95% CI, 0.32-1.73; P=0.49).
Change in Presenting Symptoms and Health-Related QOL
Mean change in leg pain from baseline for PCDT versus No PCDT was −1.76 versus −1.25 Likert points at 10 days (P=0.009), and −2.36 versus −1.80 Likert points at 30 days (P=0.008; Table 4 ). Mean change in calf circumference from baseline for PCDT versus No PCDT was −0.79 cm versus +0.22 cm at 10 days (P=0.002) and −1.37 cm versus −0.10 cm at 30 days (P<0.001). The findings for these outcomes were similar in the per-protocol analyses (Table II in the onlineonly Data Supplement).
Mean change in venous disease-specific QOL from baseline to 24 months was 28.6 versus 23.0 VEINES-QOL scale units in the PCDT versus No-PCDT Arms (between-group difference 5.6 U, P=0.029). In the perprotocol analysis, this between-group difference was 5.3 U (P=0.04). (27, 37) Symptom severity (Villalta*) class, n (%) † None or minimal (score 0-4) 24 (12) 31 (16) 55 (14) Mild (score 5-9) 65 (33) 65 (33) 130 (33) Moderate (score [10] [11] [12] [13] [14] 60 (31) 56 (29) 116 (30) Severe (score ≥ 15) 47 (24) 42 (22) 89 (23) Leg with index DVT (left), n (%) 124 (63) 125 (64) 249 (64) Previous DVT or PE, n (%) 48 (24) 45 (23) 93 (24) Previous ipsilateral DVT, n (%) 3 (2) 10 (5) 13 (3) DVT risk factors, n (%) ‡ DVT indicates deep vein thrombosis; eGFR, estimated glomerular filtration rate; IQR, interquartile range; LMWH, low molecular weight heparin; PE, pulmonary embolism; rand, randomization; and UFH, unfractionated heparin *Villalta Scale: Five patient-reported symptoms (cramps, itching, pins & needles, leg heaviness, pain) and 6 blinded clinician-reported signs (pretibial edema, skin induration, hyperpigmentation, venous ectasia, redness, pain during calf compression) scored on a 4-point scale (0=none/minimal, 1=mild, 2=moderate, 3=severe) and summed into a total score, or the presence of an ulcer (score=15), for the leg with index DVT.
†One patient in the No PCDT was not assessed. ‡Subjects may fit into >1 category. §Leg circumference with index DVT minus leg circumference of the other leg. ¶Anticoagulant (AC) therapy that was given after DVT diagnosis and before randomization. Mean change in generic QOL (physical and mental component summary scores of SF-36 measure) from baseline to 24 months did not differ for the PCDT versus No-PCDT patients in either the intention-to-treat or per-protocol analyses (P>0.25 for all analyses; Table 4,  Table II in the online-only Data Supplement).
Safety Outcomes
Within 10 days, in PCDT versus No-PCDT patients, major bleeding occurred in 3 patients (1.5%) versus 1 patient (0.5%; P=0.32), and any bleeding occurred in 7 (3.6%) versus 4 (2.1%) patients (P=0.36; Table 3 ). There were no fatal or intracranial bleeds. Recurrent venous thromboembolism within 24 months occurred in 26 (13.3%) PCDT versus 18 (9.2%) No-PCDT patients (P=0.21; none were fatal). Of the 6 deaths in each group, none occurred within 10 days postrandomization (Table 3) . Per-protocol analyses of the safety outcomes were similar (Table I in 
DISCUSSION
Contemporary clinical practice guidelines (including a Scientific Statement from the American Heart
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Association) recommend that studies of DVT therapy report outcomes separately for patients with iliofemoral versus less extensive DVT. 1,2 These and other guidelines 19, 20, 22 also identify thrombus extent as a key factor to consider when deciding which patients should receive endovascular thrombus removal, which accounts for why some randomized trials have evaluated endovascular DVT therapies exclusively in patients with iliofemoral DVT. [33] [34] [35] Consequently, this report focuses on findings in the iliofemoral DVT subgroup of the ATTRACT study.
Several studies have described favorable outcomes for aggressive thrombus removal therapies in comparison with anticoagulation alone in iliofemoral DVT, but each had major methodological limitations that undermine confidence in their findings. A small randomized trial evaluating surgical venous thrombectomy for acute iliofemoral DVT versus anticoagulation alone reported improved long-term iliofemoral patency and reduced postthrombotic morbidity in the surgically-treated patients. 36 A post hoc analysis of data from a prospective multicenter registry found that 68 CDT-treated patients had significantly fewer PTS symptoms, better physical functioning, less stigmata of chronic venous insufficiency, and less health distress (P<0.05 for all outcomes) at a mean follow-up of 16 months compared with 30 retrospectively matched patients who were treated with PTS indicates postthrombotic syndrome; VCSS, Venous Clinical Severity Score; and VTE, venous thromboembolism. *Cochran-Mantel-Haenszel (CMH) test adjusted for center, cumulative proportion of patients who developed PTS at any time between 6 and 24 mo, inclusive. Villalta scores (0-33 range), VCSS scores (0-27 range); higher is worse for both.
†At each visit, the proportion of patients with any PTS according to the Villalta scale among those who had an assessment performed (denominator). ‡Cumulative proportion with moderate or severe PTS (prespecified analysis). §At each visit, the proportion of patients with moderate or severe PTS according to the Villalta scale among those who had an assessment performed (denominator).
¶Cumulative proportion with severe PTS ‖Composite of PTS or major non-PTS treatment failure.
Circulation. ORIGINAL RESEARCH ARTICLE anticoagulation alone. 9 A prospective, nonrandomized study (n=51) found better 6-month and 5-year venous patency and freedom from venous symptoms in patients who received CDT versus anticoagulation alone. 37 Finally, a single-center randomized trial comparing streptokinase CDT versus anticoagulation alone observed a higher rate of normal venous function and less valvular reflux in CDT recipients. 38 However, these studies were limited by potential selection bias and baseline differences between treatment groups attributable to their nonrandomized design, 9,37 small sample size, 9, [36] [37] [38] performance in a single center, 37, 38 and lack of rigorous PTS assessment with validated tools. 38 A recent multicenter, randomized trial that evaluated CDT for proximal DVT above midthigh level (the CAVENT trial [Catheter-directed Venous Thrombolysis]) found that CDT reduced PTS, which significantly correlated with patency of the ipsilateral iliofemoral venous segment.
11,13
Because CAVENT did not report outcomes separately for iliofemoral DVT and femoral-popliteal DVT patients, we are unable to combine data from the iliofemoral subgroups of the 2 trials. Although in the total study population, CAVENT reported that CDT reduced any PTS, CDT did not improve long-term QOL and was associated with major and nonmajor bleeding complications. Consequently, we suggest that the findings of ATTRACT and CAVENT collectively argue against routine first-line thrombolysis for proximal DVT, but that patients with iliofemoral DVT or more severe presentations may derive benefit and deserve further examination.
This exploratory analysis of the iliofemoral DVT subgroup in the ATTRACT Trial did not find an effect of PCDT on the development of any PTS over 2 years using the prespecified primary trial outcome (Villalta score threshold of 5), and did not find an effect on bleeding. These findings were similar in the per-protocol analysis, and they are consistent with PCDT treatment effects for any PTS in the iliofemoral and femoral-popliteal subgroups that did not differ significantly (P interaction=0.85). 18 Although PCDT reduced the occurrence of PTS in a prespecified secondary assessment using the VCSS, we chose the Villalta scale as the trial's primary outcome measure based on a more extensive body of literature and international societal recommendations supporting its use to detect incident PTS, including more rigorous assessment of the Villalta threshold score than the VCSS threshold score. [23] [24] [25] [26] Additional studies to compare the performance characteristics of these 2 PTS scales, using the ATTRACT and other datasets, would be worthwhile.
The data from this analysis collectively suggest that PCDT improves short-term recovery from DVT and reduces long-term progression of PTS severity in patients with iliofemoral DVT. Evidence favoring PCDT includes the following: (1) greater reduction in leg pain and swelling through 30 days (P<0.01); (2) reduced PTS severity (P<0.01 for Villalta and VCSS comparisons) at 6, 12, 18, and 24 months; (3) reduced occurrence of moderate-or-severe PTS (P=0.021 for comparison of proportion with Villalta ≥ 10) and severe PTS (P<0.05 for comparisons of proportions with Villalta ≥ 15 and VCSS ≥ 8) through 24 months; and (4) greater improvement in venous disease-specific QOL from baseline to 24 months (5.6 points on VEINES-QOL scale, P=0.029). These findings were consistent in the perprotocol analyses.
However, the findings of this analysis should not be considered conclusive evidence that PCDT reduces 
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the occurrence of moderate-or-severe PTS in patients with iliofemoral DVT. Moderate-or-severe PTS was 1 of a number of secondary outcomes. Although assessors were blinded to treatment arm, healthcare providers and patients were not blinded. Hence, further studies are recommended to determine whether PCDT truly reduces moderate-or-severe PTS in patients with iliofemoral DVT. In this analysis, there was a suggestion that PCDT exerted a more positive effect on the moderate-or-severe PTS outcome in iliofemoral DVT patients who were <65 years of age versus those ≥65 years old (P interaction = 0.04), and on patients whose DVT was provoked by a major reversible risk factor (P interaction = 0.05). However, because these 2 results are in subgroups within the iliofemoral subgroup, and because they are among many outcomes that were evaluated in the study, and because the tests of interaction were not strongly positive, these 2 findings may have occurred by chance. 39, 40 Our analysis has several limitations. First, there was substantial loss to follow-up that was unbalanced between the treatment groups (more missed PTS assessments in the No-PCDT Arm), which influenced the study's estimates of treatment effects. 18 Because only 57% of ATTRACT Trial patients had iliofemoral DVT, power to detect differences in outcomes with PCDT versus No-PCDT in the iliofemoral DVT subgroup is substantially less than in the overall trial. Furthermore, in *Mean scores, standard errors (SE), and treatment differences estimated using growth curve models and piece-wise linear regression adjusted for center, and baseline covariates (age, sex, body mass index, race).
†Villalta scores (0-33 range) -higher is worse. ‡Mean scores, standard errors (SE), and treatment differences estimated using growth curve models and piece-wise linear regression adjusted for center, and baseline covariates (age, sex, body mass index, race, Villalta score).
§VCSS scores (0-27 range) -higher is worse. ¶Model estimates are unchanged from month 6 to month 12 because of the lack of a significant time trend. ‖SF-36 major scales: PCS (0-100 range) and MCS (0-100 range) -higher is better, with a difference of 3 to 4 points considered clinically meaningful. **VEINES overall score (0-100 range) and symptom-specific score (0-100 range) -higher is better. † †Mean change scores, SEs, and treatment differences estimated using multiple linear regression adjusted for center. ‡ ‡Patient-reported severity of pain in the index leg (0-7 range) -higher is worse. § §Leg circumference measured at 10 cm below tibial tuberosity of the index leg.
Circulation. ORIGINAL RESEARCH ARTICLE the absence of a statistically significant test of interaction to support a difference in the PCDT treatment effect on moderate-or-severe PTS between the iliofemoral and femoral-popliteal subgroups, the treatment effect estimate from the overall trial may be the most reliable estimate of the treatment effect in each of these 2 subgroups. 39, 40 This is also true for the assessment of bleeding, which was statistically higher with use of PCDT in the overall ATTRACT Trial. On the other hand, tests of interaction to detect differences in treatment effects between subgroups have low power in a medium-sized study such as ATTRACT. Strengths of this analysis include that it was prespecified, that the presence of iliofemoral DVT was a stratification variable that was identified before randomization, and that the reduction in PTS severity with PCDT was a consistent finding across multiple venous outcome measures. We excluded patients with either asymptomatic DVT or DVT causing acute circulatory compromise because they could not be ethically randomized to one or the other treatment strategy, and we acknowledge that (1) the enrolled patients had varying baseline symptom severity (and perhaps PTS risk), (2) patients with recurrent ipsilateral DVT within the last 2 years (who are expected to have a high risk of PTS) were excluded, and (3) site investigators could have chosen to bypass the study for selected patients at either end of the severity spectrum. However, throughout the study we provided detailed education to study centers that explicitly addressed this issue and strongly encouraged the enrollment of all willing iliofemoral DVT patients who 
met the study eligibility criteria. This analysis is also the largest report of randomized trial outcomes specifically in patients with iliofemoral DVT.
In conclusion, the findings of this exploratory analysis strongly suggest that PCDT reduces acute leg pain and swelling, reduces PTS severity, and improves venous QOL in patients with acute iliofemoral DVT. These findings support early use of PCDT in patients with acute iliofemoral DVT who have severe symptoms, low bleeding risk, and who attach greater importance to a reduction in early and late symptoms than to the risks, cost, and inconvenience of PCDT. A decision to use PCDT should factor in this study's limitations (including the lack of patient blinding) and should be made only after a careful review of the bleeding risk in that individual patient. Further prospective study of PCDT and other endovascular therapies should be targeted to the subset of patients with iliofemoral DVT. 
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